While the market fixates on the STELARA patent cliff, the rest of the story is being missed. That drug now represents a small fraction of the Innovative Medicine portfolio. The remaining 96% of that business is posting remarkable growth, expanding at over 14%.

Antiarrhythmic agents account for around 55% of the therapy landscape, while monoclonal antibodies are emerging as an investigational approach Atrial Fibrillation Market Atrial Fibrillation Market Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Market by Treatment, Type of Drug, Type of Drug Molecule, Type of Target, Route of Administration, Type of Device, Type of Technology, End User, Geographical Regions and Sales Forecast - Trends and Forecast Till 2035" has been added to

Opportunities center on pulsed field ablation, advanced mapping catheters and LAAC implants, driven by aging populations and demand for safer, drug-free care. Asia-Pacific expansion, ambulatory procedures, improving reimbursement and regulatory support offer further growth. Atrial Fibrillation Treatment Devices Market Atrial Fibrillation Treatment Devices Market Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Devices Market by Type of Device, Type of Technology, End

Johnson & Johnson (NYSE: JNJ) received FDA approval for IMAAVY as the first treatment for adults with warm autoimmune hemolytic anemia, providing a new option for this rare blood disorder. The decision expands Johnson & Johnson's presence in rare diseases, with IMAAVY targeting patients who face limited existing therapies. In a separate development, a jury awarded a US$10 million verdict in a talc-related mesothelioma case against Johnson & Johnson, adding to its ongoing litigation...

Johnson & Johnson's stock reached $270.24, close to its 52-week high of $276.47, following raised full-year guidance and FDA approval of a new robotic surgical system. The company shows strong growth in oncology and immunology, with key products like Darzalex and Tremfya performing well. Despite a 32% year-to-date gain and a solid dividend, the stock is considered fully valued at current levels, with limited upside potential until further growth catalysts emerge. Investors are advised to hold and watch for signs of acceleration in the second half of the year or any risks such as litigation or operational delays.

Johnson & Johnson expands TECVAYLI use in Europe, strengthening its multiple myeloma portfolio and advancing its broader oncology strategy.

Johnson and Johnson has surged over 54% in a year, cleared a major FDA hurdle, and raised its guidance, yet something about the current setup gives pause before hitting buy.

Johnson and Johnson has surged over 54% in a year, cleared a major FDA hurdle, and raised its guidance, yet something about the current setup gives pause before hitting buy.